Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers

被引：20

作者：

Özdemir, V ^{[1
]}

Tyndale, RF

Reed, K

Herrmann, N

Sellers, EM

Kalow, W

Naranjo, CA

机构：

[1] Univ Toronto, Dept Pharmacol, Toronto, ON M4N 3M5, Canada

[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Psychopharmacol Res Program, Toronto, ON M4N 3M5, Canada

[3] Univ Toronto, Womens Coll Hosp, Psychopharmacol & Dependence Res Unit, Toronto, ON M4N 3M5, Canada

[4] Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M4N 3M5, Canada

[5] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M4N 3M5, Canada

[6] Univ Toronto, Dept Psychiat, Toronto, ON M4N 3M5, Canada

[7] Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada

来源：

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 19卷 / 05期

关键词：

D O I：

10.1097/00004714-199910000-00014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：472 / 475

页数：4

共 50 条

[31] EFFECT OF PAROXETINE ON THE PHARMACOKINETICS OF ATOMOXETINE IN DIFFERENT CYP2D6 GENOTYPE
Kim, S. H.
Byeon, J. Y.
Kim, Y. H.
Lee, H. J.
Lee, Y.
Lee, Y. J.
Kim, D. H.
Lim, H. J.
Lee, S. Y.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E60 - E60
[32] Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
Mihara, K
Otani, K
Suzuki, A
Yasui, N
Nakano, H
Meng, XM
Ohkubo, T
Nagasaki, T
Kaneko, S
Tsuchida, S
Sugawara, K
Gonzalez, FJ
PSYCHOPHARMACOLOGY, 1997, 133 (01) : 95 - 98
[33] Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
Kazuo Mihara
K. Otani
Akihito Suzuki
Norio Yasui
Hajime Nakano
Xianmin Meng
Tadashi Ohkubo
Takako Nagasaki
Sunao Kaneko
Shigeki Tsuchida
Kazunobu Sugawara
Frank J. Gonzalez
Psychopharmacology, 1997, 133 : 95 - 98
[34] Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
Morita, S
Shimoda, K
Someya, T
Yoshimura, Y
Kamijima, K
Kato, N
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) : 141 - 149
[35] CYP2D6 inhibition by selective serotonin reuptake inhibitors: Analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6
Lam, YWF
Gaedigk, A
Ereshefsky, L
Alfaro, CL
Simpson, J
PHARMACOTHERAPY, 2002, 22 (08): : 1001 - 1006
[36] Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
Birgit M. Wollmann
Elisabet Størset
Marianne Kristiansen Kringen
Espen Molden
Robert L. Smith
European Journal of Clinical Pharmacology, 2023, 79 : 523 - 531
[37] Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
Li, Susie Xiujiang
Pequignot, Edward
Panebianco, Deborah
Lupinacci, Paul
Majumdar, Anup
Rosen, Laura
Ahmed, Tuli
Royalty, Lane E.
Rushmore, Thomas H.
Murphy, M. Gail
Petty, Kevin J.
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (07): : 792 - 801
[38] Modelling the pharmacokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers
Di Patti, F.
Fanelli, D.
Pedersen, R. S.
Giuliani, C.
Torricelli, F.
JOURNAL OF THEORETICAL BIOLOGY, 2008, 254 (03) : 568 - 574
[39] Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers
DeVane, CL
Markowitz, JS
Carson, SW
Boulton, DW
Gill, HS
Nahas, Z
Risch, SC
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) : 347 - 349
[40] Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
Dilger, K
Greiner, B
Fromm, MF
Hofmann, U
Kroemer, HK
Eichelbaum, M
PHARMACOGENETICS, 1999, 9 (05): : 551 - 559

← 1 2 3 4 5 →